Micot (02335.HK): Phase‑II Clinical Trial of MT200605 for Acute Ischemic Stroke Completed, AKI Incidence Reduced by Over 80% in High‑dose Cohort

NewTimeSpace News: On August 26, 2026,Micot(02335.HK) announced the completion of its Phase‑II clinical trial of MT200605 for acute ischemic stroke. A total of 360 subjects were randomised in a 1:1:1:1 ratio into low‑dose, medium‑dose, high‑dose and placebo cohorts, receiving 14‑day consecutive intravenous infusions.

According to the announcement, for the primary efficacy endpoint, the proportion of patients achieving mRS≤1 in the high‑dose cohort was significantly higher than in the placebo group with statistically significant difference, demonstrating a clear dose‑response relationship. From the safety perspective, the incidence of AKI in the high‑dose cohort fell by over 80% compared with the placebo group. MT200605 is a first‑in‑class small‑molecule TrkB agonist capable of crossing the blood‑brain barrier.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.